• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5100867)   Today's Articles (0)
Download
Rank Citation Analysis Article
Type
Number of Years Citation(s) in RCA
1
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2019;381:13-24. [PMID: 31150574 DOI: 10.1056/nejmoa1903307] [Citation(s) in RCA: 952] [Impact Index Per Article: 158.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Clinical Trial, Phase III 6 952
2
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med 2018;378:1408-1418. [PMID: 29420164 DOI: 10.1056/nejmoa1715546] [Citation(s) in RCA: 919] [Impact Index Per Article: 131.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Clinical Trial, Phase III 7 919
3
Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Zhang K, Lopez-Gitlitz A, Smith MR. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol 2019;30:1813-1820. [PMID: 31560066 PMCID: PMC6927320 DOI: 10.1093/annonc/mdz397] [Citation(s) in RCA: 105] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]  Open
Clinical Trial, Phase III 6 105
4
Uemura H, Koroki Y, Iwaki Y, Imanaka K, Kambara T, Lopez-Gitlitz A, Smith A, Uemura H. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol 2020;20:139. [PMID: 32878613 PMCID: PMC7465330 DOI: 10.1186/s12894-020-00689-0] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Accepted: 07/29/2020] [Indexed: 02/01/2023]  Open
Clinical Trial, Phase I 5 36
5
Gupta E, Guthrie T, Tan W. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). BMC Urol 2014;14:55. [PMID: 25062956 PMCID: PMC4167156 DOI: 10.1186/1471-2490-14-55] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2014] [Accepted: 07/17/2014] [Indexed: 11/14/2022]  Open
Review 11 25
6
Belderbos BPSI, de Wit R, Chien C, Mitselos A, Hellemans P, Jiao J, Yu MK, Attard G, Bulat I, Edenfield WJ, Saad F. An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2018;82:457-468. [PMID: 29974203 PMCID: PMC6105166 DOI: 10.1007/s00280-018-3632-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Accepted: 06/22/2018] [Indexed: 01/16/2023]
Clinical Trial, Phase I 7 12
7
Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, Fisher P, Ellenberg J. Evaluation of albutoin as an antiepileptic drug. Clin Pharmacol Ther 1974;15:406-16. [PMID: 4206927 DOI: 10.1002/cpt1974154406] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Clinical Trial 51 8
8
Posadas EM, Chi KN, de Wit R, de Jonge MJA, Attard G, Friedlander TW, Yu MK, Hellemans P, Chien C, Abrams C, Jiao JJ, Saad F. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Clin Cancer Res 2020;26:3517-3524. [PMID: 32366670 DOI: 10.1158/1078-0432.ccr-19-3402] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Revised: 03/20/2020] [Accepted: 04/28/2020] [Indexed: 12/24/2022]
Clinical Trial, Phase I 5 5
9
Borno HT, Small EJ. Apalutamide and its use in the treatment of prostate cancer. Future Oncol 2019;15:591-599. [PMID: 30426794 PMCID: PMC6391625 DOI: 10.2217/fon-2018-0546] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2018] [Accepted: 10/09/2018] [Indexed: 12/23/2022]  Open
Review 6 5
10
Reis LO. Metastasis-free Survival-Progress or Lowering the Bar on Nonmetastatic Prostate Cancer? Eur Urol 2018;74:682-683. [PMID: 30170874 DOI: 10.1016/j.eururo.2018.08.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2018] [Accepted: 08/10/2018] [Indexed: 11/27/2022]
Letter 7 4
11
Matsuura M, Hayashi Y, Katayama H. Duodenal ulcer in rats by 3-allyl-5-isobutyl-2-thiohydantoin and its related compound. EXPERIENTIA 1973;29:1364-5. [PMID: 4761240 DOI: 10.1007/bf01922820] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
52 1
12
Palmieri VE, Roviello G, D'Angelo A, Casadei C, De Giorgi U, Giorgione R. Darolutamide in hormone-sensitive and castration-resistant prostate cancer. Expert Rev Clin Pharmacol 2021;14:535-544. [PMID: 33685318 DOI: 10.1080/17512433.2021.1901580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 03/08/2021] [Indexed: 10/22/2022]
Comparative Study 4 0
13
Córdoba Sánchez J, Monge-Escartín I, Gil J, Carrera C, Sáez-Peñataro J, Ferrer L, Aversa C, Mellado B, Mases J, Ribal MJ, Alcaraz A, Vilaseca A. Real-world study: Impact of multidisciplinary management of apalutamide-associated adverse events in prostate cancer. Prostate 2024;84:1198-1208. [PMID: 38888199 DOI: 10.1002/pros.24755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Revised: 04/25/2024] [Accepted: 06/05/2024] [Indexed: 06/20/2024]
Observational Study 1
14
Umehara K, Saito Y, Takada S, Yamagishi K, Takada N, Maruyama S, Harabayashi T, Hashishita H. Pharmacist Intervention in Outpatients With Prostate Cancer Prevents Apalutamide-induced Skin Adverse Events. In Vivo 2025;39:459-466. [PMID: 39740884 PMCID: PMC11705145 DOI: 10.21873/invivo.13849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2024] [Revised: 11/08/2024] [Accepted: 11/11/2024] [Indexed: 01/02/2025]
research-article 1
15
Suzuki K, Shiraishi Y, Okamura Y, Bando Y, Hara T, Okada K, Terakawa T, Hyodo Y, Chiba K, Teishima J, Nakano Y, Miyake H. Dose Per Body Weight Predicts Incidence and Severity of Apalutamide-Related Skin Rash in Metastatic Castration-Sensitive Prostate Cancer. Clin Genitourin Cancer 2025;23:102250. [PMID: 39571520 DOI: 10.1016/j.clgc.2024.102250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2024] [Revised: 10/16/2024] [Accepted: 10/20/2024] [Indexed: 01/25/2025]
1
16
Gil-Lianes J, Amat-Samaranch V, Giavedoni P, Vilaseca A, Córdoba Sánchez J, Alamon-Reig F, Castillo P, Garcia AP, Pascal M, Carrera C. Cutaneous Adverse Reactions to Apalutamide: Case Series with Clinical and Pathological Correlations. Acta Derm Venereol 2024;104:adv40719. [PMID: 39233615 PMCID: PMC11382552 DOI: 10.2340/actadv.v104.40719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2024] [Accepted: 08/06/2024] [Indexed: 09/06/2024]  Open
Case Reports 1
17
Wang Q, Ren ZT, Wu HF, Gu HC, Li XW, Tang ZL. Dermatological adverse events in Chinese prostate cancer patients treated with the androgen receptor inhibitor apalutamide. Front Immunol 2025;16:1530919. [PMID: 40051628 PMCID: PMC11882852 DOI: 10.3389/fimmu.2025.1530919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2024] [Accepted: 02/04/2025] [Indexed: 03/09/2025]  Open
research-article 1
18
Marx G, Chowdhury S, Krieger L, Hovey E, Shapiro J, Tran B, Tan TH, Ng S, Woo HH. A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia. Asia Pac J Clin Oncol 2024;20:435-443. [PMID: 38639402 DOI: 10.1111/ajco.14054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 06/01/2023] [Accepted: 02/25/2024] [Indexed: 04/20/2024]
Review 1
19
Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Soto ÁJ, Uemura H, Ye DW, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN. Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study. Future Oncol 2024;20:563-578. [PMID: 38126311 DOI: 10.2217/fon-2023-0649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 11/17/2023] [Indexed: 12/23/2023]  Open
Patient Education Handout 1
20
Hegele A, Häußermann R, Schultheis S, Skrobek L, Vink M, Hollwegs S, Ludwig M, Huwe P, Maywurm M, Bartsch-Polle A, Weber J, Thiemer M, Varughese D. Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study. J Cancer Res Clin Oncol 2024;150:414. [PMID: 39249593 PMCID: PMC11384626 DOI: 10.1007/s00432-024-05928-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Accepted: 08/16/2024] [Indexed: 09/10/2024]
Multicenter Study 1
21
David K, Van Crombrugge P, Van der Biest AM, D’Hondt F, Claessens F, Giesen A, Joniau S, Decallonne B. Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management. Eur Thyroid J 2024;13:e240158. [PMID: 39419092 PMCID: PMC11558953 DOI: 10.1530/etj-24-0158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2024] [Accepted: 09/17/2024] [Indexed: 10/19/2024]  Open
Case Reports 1
22
Encarnación Navarro JA, Morillo Macías V, Borrás Calbo M, De la Fuente Muñoz I, Lozano Martínez A, García Martínez V, Fernández Fornos L, Guijarro Roche M, Amr Rey O, García Gómez R. Multicenter Real-World Study: 432 Patients with Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer. Curr Oncol 2025;32:119. [PMID: 40136324 PMCID: PMC11941571 DOI: 10.3390/curroncol32030119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2025] [Revised: 02/17/2025] [Accepted: 02/20/2025] [Indexed: 03/27/2025]  Open
Multicenter Study 1
23
Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR, Graff JN. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. Br J Cancer 2024;130:73-81. [PMID: 37951974 PMCID: PMC10781967 DOI: 10.1038/s41416-023-02492-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 10/25/2023] [Accepted: 11/01/2023] [Indexed: 11/14/2023]  Open
research-article 1
24
Santoni M, Büttner T, Rescigno P, Fiala O, Cavasin N, Basso U, Taha T, Massari F, Myint ZW, Formisano L, Galli L, Scagliarini S, Matrana MR, Facchini G, Bamias A, Messina C, Zacchi F, Manneh RK, Roviello G, Santini D, Poprach A, Navratil J, Uher M, Calabrò F, Pierce E, Berardi R, Aurilio G, Zakopoulou R, Rizzo A, Ansari J, Rizzo M, Bisonni R, Mollica V, Incorvaia L, Spinelli G, Jiang XY, Chandler RA, Grillone F, Morelli F, Buti S, Maluf FC, Marques Monteiro FS, Battelli N, Porta C, Caffo O, Soares A. Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study. Eur Urol Oncol 2025;8:444-451. [PMID: 39613567 DOI: 10.1016/j.euo.2024.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2024] [Revised: 10/23/2024] [Accepted: 11/05/2024] [Indexed: 12/01/2024]
Multicenter Study 1
25
Honma Y, Monden N, Yamazaki K, Kano S, Satake H, Kadowaki S, Utsumi Y, Nakatogawa T, Takano R, Fujii K, Koroki Y, Aoyama J, Ouchi S, Ogawa T, McCarthy S, Brookman-May SD, Mundle S, Li J, Thaper D, Nagao T, Tada Y. Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU. Clin Cancer Res 2024;30:3416-3427. [PMID: 38940667 DOI: 10.1158/1078-0432.ccr-24-0455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Revised: 04/09/2024] [Accepted: 06/26/2024] [Indexed: 06/29/2024]
Clinical Trial, Phase II 1
Please SIGN IN to browse more articles.
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Excel